A role for lysosomal phospholipase A2 in drug induced phospholipidosis.
Many therapeutic drugs currently in use are cationic amphiphiles. These cationic amphiphilic drugs (CADs) induce phospholipidosis in humans and experimental animals. The recent study shows that CAD-induced cellular phospholipidosis is linked to the impairment of phospholipid catabolism by inhibition of lysosomal phospholipase A2 activity.
Abe
Akira
A
University of Michigan Medical Center, Department of Internal Medicine, Division of Nephrology, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0676, USA. aabe@umich.edu
Hiraoka
Miki
M
Shayman
James A
JA
D000818:Animals; D002412:Cations; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008064:Lipidoses / Q000139:chemically induced* / Q000503:physiopathology; D008247:Lysosomes / Q000201:enzymology; D004364:Pharmaceutical Preparations / Q000737:chemistry; D064801:Phospholipase A2 Inhibitors; D010743:Phospholipids / Q000378:metabolism; D013501:Surface-Active Agents / Q000009:adverse effects / Q000737:chemistry
D002412:Cations; D004364:Pharmaceutical Preparations; D064801:Phospholipase A2 Inhibitors; D010743:Phospholipids; D013501:Surface-Active Agents